Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU

Dow Jones2023-11-23

By Adriano Marchese

Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union.

The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis.

Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF.

Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 23, 2023 09:24 ET (14:24 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2385624794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-23 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2385624794","market":"fut","top_or_hot":-1,"title":"Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union. \n</p>\n<p>\n  The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis. \n</p>\n<p>\n  Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF. \n</p>\n<p>\n  Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 23, 2023 09:24 ET (14:24 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-11-23 22:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union. \n</p>\n<p>\n  The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis. \n</p>\n<p>\n  Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF. \n</p>\n<p>\n  Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 23, 2023 09:24 ET (14:24 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0079474960.USD","symbol_name":"联博美国增长基金A","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2385624794","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2385624794","pubTimestamp":1700749440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union.The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis.Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF.Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0079474960.USD":"联博美国增长基金A","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","VRTX":"福泰制药","BK4023":"应用软件","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","VERX":"Vertex, Inc.","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4156":"煤与消费用燃料","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","EU":"ENCORE ENERGY CORP","LU0058720904.USD":"联博国际健康护理基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"Vertex Pharmaceuticals在欧盟批准用于幼儿囊性纤维化治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EU":1,"VERX":1,"VRTX":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union. \n\n\n  The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis. \n\n\n  Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF. \n\n\n  Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 23, 2023 09:24 ET (14:24 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2385624794","isCrawlerRequest":true}